Sanofi's three innovative drugs enter the 2024 national medical insurance catalog
cannytjy
发表于 2024-12-5 07:52:15
3381
0
0
On November 28th, the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024)" was officially announced. Sanofi's three innovative drugs are among them, including Dabitou& reg; (Dupilumab injection) successfully renewed contract, Yilaike& reg; (Besudil Methanesulfonate Tablets) and Zhilida& reg; Rosuvastatin ezetimibe tablets (I) have been included in the medical insurance catalog for the first time. The revised version of the medical insurance drug catalog will be officially implemented from January 1, 2025.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Eli Lilly Pharmaceuticals: Several products, including Abercillin tablets, have been included in the new national medical insurance catalog
- Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
- Sanofi's three innovative drugs enter the 2024 national medical insurance catalog